JSON
Christoffersson G, von Herrath M
Trends Immunol. 40 (6) 482-491 [2019-06-00; online 2019-05-14]
In autoimmunity, aggressive immune responses are counteracted by suppressive rejoinders. For instance, FOXP3-expressing regulatory T cells (Tregs), have shown remarkable effects in limiting autoimmunity in preclinical models. However, early results from human Treg trials have not been as positive. Here, we highlight questions surrounding Treg transfers as putative treatments for autoimmunity. We discuss whether lack of antigenic recognition might be key to shifting cells from contributing to an aggressive autoresponse, to being part of a regulatory network. Moreover, we argue that identifying the physiological range of immunosuppression of Tregs might help potentiate their efficacy. We propose widening the view on immunoregulation by considering the participation of CD8+ Tregs in this process, which could have major implications in autoimmunity.
PubMed 31101537
DOI 10.1016/j.it.2019.04.005
Crossref 10.1016/j.it.2019.04.005
pii: S1471-4906(19)30079-1